threewheeler
3 years ago
LTUS SECURITY DETAILS fantastic float now
Share Structure
Market Cap Market Cap
24,250,640
08/03/2022
Authorized Shares
3,000,000,000
08/03/2022
Outstanding Shares
2,694,515,543 250m gone
08/03/2022
Restricted
2,681,123,970
08/03/2022
Unrestricted
13,391,573 250m gone from float as well
08/03/2022
Held at DTC
12,913,385
08/03/2022 Authorized Shares
3,000,000,000
11/28/2021
Outstanding Shares
2,944,515,543
11/28/2021
Restricted
2,681,123,970
11/28/2021
Unrestricted
263,391,573
11/28/2021
threewheeler
3 years ago
LTUS SECURITY DETAILS
Share Structure
Market Cap Market Cap
68,459,986
11/26/2021
Authorized Shares
3,000,000,000
11/28/2021
Outstanding Shares
2,944,515,543
11/28/2021
Restricted
2,681,123,970
11/28/2021
Unrestricted
263,391,573
11/28/2021
Held at DTC
12,903,385
11/28/2021
Steppenwolf$$$
6 years ago
FEBRUARY 12, 2019
Alvogen
launches
the
first
generic
equivalent
to
Revlimid™
in
Europe
Alvogen today announced the launch of the first generic equivalent of Revlimid™ (lenalidomide) in several CEE markets including Romania, Croatia, Bulgaria and the Baltic states. The product will be marketed as 2.5, 5, 7.5, 10, 15, 20, 25mg hard capsules and is a fully generic and bioequivalent product to Revlimid™. Following the launch into multiple CEE countries, Alvogen’s Lenalidomide will also be launched in selected Asian countries in 2019.
Alvogen’s Lenalidomide has been developed fully in-house at Alvogen‘s subsidiary, Lotus Pharmaceuticals and is part of a comprehensive oncology pipeline
Steppenwolf$$$
6 years ago
LTUS Alvogen’s Chairman & CEO Robert Wessman is the new Chairman of the Board at the publicly listed Lotus Pharmaceuticals in Taiwan, succeeding Andrew Lin. Lotus Pharmaceuticals, $5B COMPANY FEBRUARY 12, 2019
Alvogen
launches
the
first
generic
equivalent
to
Revlimid™
in
Europe
Alvogen today announced the launch of the first generic equivalent of Revlimid™ (lenalidomide) in several CEE markets including Romania, Croatia, Bulgaria and the Baltic states. The product will be marketed as 2.5, 5, 7.5, 10, 15, 20, 25mg hard capsules and is a fully generic and bioequivalent product to Revlimid™. Following the launch into multiple CEE countries, Alvogen’s Lenalidomide will also be launched in selected Asian countries in 2019.
Alvogen’s Lenalidomide has been developed fully in-house at Alvogen‘s subsidiary, Lotus Pharmaceuticals and is part of a comprehensive oncology pipeline.